Compare AbCellera Biologics Inc (ABCL) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Modine Manufacturing Company — how do they compare? AbCellera Biologics Inc trades at $9.28 (market cap $2.85B), while Modine Manufacturing Company trades at $198.81 (market cap $10.15B). The key difference: Modine Manufacturing Company is far larger — about 3.6× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| ABCL | MOD | |
|---|---|---|
Market Cap | $2.85B | $10.15B |
Sector | Health | Technology |
52-Week High | $9.34 | $306.89 |
52-Week Low | $2.78 | $119.68 |
Enterprise Value | $2.45B | $10.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Modine Manufacturing (MOD) trades at $195.60, up 1.6% on the day, with a bearish technical signal but strong fundamental growth driven by data center demand. The stock shows stretched valuation with a P/E of 71.27, yet has beaten earnings estimates for three consecutive quarters. Recent news highlights surging data center sales but also margin pressure and supply-chain constraints.
Outlook is mixed: robust revenue growth and a $319 consensus price target suggest upside, but high valuation, margin compression, and technical weakness pose risks. Investors should weigh strong analyst buy ratings against execution challenges in a competitive thermal management market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
